Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.
How it helps
Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.
With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.
How it works
Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.
Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.
Scrips global team of journalists span key markets around the clock
Get exclusive access to accurate data, timely insights and trusted analysis that delivers to gain competitive advantage
Access interviews with leading decision makers, industry experts and thought leaders, across the industry.
Put your questions about any of our news stories, data and analysis to our expert journalists and analysts.
Scrip
By Brian Yang 14 Jun 2018
Recent biotech investment deals involving WuXi, Oncologie and Siranomics show Chinese investors are becoming increasingly bold and savvy in betting on innovative assets both inside and outside the country.
Topic BioPharmaceutical
Scrip
By Joseph Haas 14 Jun 2018
Having previously criticized the biopharma industry for squandering the benefits of US tax reform, the former Teva CEO called for more M&A deals that offer a clear strategic rationale, pointing to Takeda/Shire as an example.
Topic BioPharmaceutical
Scrip
By Emily Hayes 06 Jun 2018
The cancer immunotherapy combo showed "remarkable" effects in patients who tested negative for PD-L1 expression and would normally not respond well to immunotherapy.
Scrip
By Jessica Merrill 06 Jun 2018
Investors weren't wildy impressed by the data at ASCO this year, but for pharma, the meeting felt like a renewal, a re-commitment to getting it right. It was more a year of refinement as industry digests the advances that have been made, the big mistakes, and pivots toward where to go next.
Topic Cancer
Scrip
By Emily Hayes 04 Jun 2018
In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.
Scrip
By Eleanor Malone 01 Jun 2018
Peter Guenter has steadied the ship at Almirall, and after seven months in the role he outlines his vision for the company in his first exclusive interview as CEO of Spain's largest pharma company.
Citeline, Scrip, Biomedtracker, Datamonitor Healthcare
By Loni Branon 29 May 2018
Just in time for your 2018 ASCO Annual Meeting planning, join analysts from Datamonitor Healthcare, Biomedtracker, Citeline, Scrip, and Pink Sheet for their expert opinions on what you need to know to get the most from the meeting. Let our experts present their top picks from the thousands of abstracts being presented at ASCO.
Topic Clinical trials
Scrip
By Ian Haydock 25 May 2018
Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key products reach the global market and others begin to face biosimilar competition. In this first part of a two-part exclusive interview, he outlines the firm's vision, approach to R&D and how the strategic alliance with Roche is playing out.
Topic Business strategies Research
Scrip
By Jessica Merrill 25 May 2018
The price of new oncology brands doubled in the US from 2013 to 2017, bringing the median annual price to more than $160,000 last year, up from $79,000 in 2013, according to a new IQVIA report. Spending on cancer drugs in the US has doubled since 2012, reaching nearly $50bn in 2017.
Topic Cancer
Scrip
By Brenda Sandburg 23 May 2018
Xtandi use in early prostate cancer, lorlatinib as second-line treatment for non-small cell lung cancer and dacomitinib for first-line NSCLC have upcoming user fee dates.
Topic Cancer
Scrip
By Brian Yang 23 May 2018
As the Congo grapples with the latest outbreak of Ebola, China has approved its first domestically developed vaccine in record time, hailing it a national innovation champion. But as the World Health Organization starts vaccinations in Africa, can China make the cut and compete with global players including Merck & Co?
Topic Vaccines
Scrip
18 May 2018
The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."
Topic Brexit Business strategies
Scrip
By Emily Hayes 18 May 2018
Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.
Topic Cancer
Scrip
By Mandy Jackson 16 May 2018
Beam Therapeutics combines new insights from gene-editing pioneers to allow for single-letter editing of DNA and RNA. The company has raised $87m to develop DNA base-editing for therapies that in some diseases could be more efficient than CRISPR gene editing.
Scrip
By Emily Hayes 16 May 2018
There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.
Topic Cancer
Scrip
18 Jun 2018
Scrip
17 Jun 2018
Scrip
15 Jun 2018
Scrip
15 Jun 2018
Scrip
15 Jun 2018
Scrip
15 Jun 2018
Scrip
15 Jun 2018
Scrip
15 Jun 2018
Scrip
15 Jun 2018
Scrip
14 Jun 2018
Scrip
14 Jun 2018
Scrip
14 Jun 2018
Scrip
14 Jun 2018
Scrip
14 Jun 2018
Scrip
14 Jun 2018
UK
+31 year(s) experience
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
From discovery to patent expiry, and coverage spanning both ethical and generic drugs, Medtrack has you covered. Stay current on key financing, drug and biologics development and drug manufacturing information, all with a single tool.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Keep up to date